JP2005518365A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005518365A5 JP2005518365A5 JP2003547372A JP2003547372A JP2005518365A5 JP 2005518365 A5 JP2005518365 A5 JP 2005518365A5 JP 2003547372 A JP2003547372 A JP 2003547372A JP 2003547372 A JP2003547372 A JP 2003547372A JP 2005518365 A5 JP2005518365 A5 JP 2005518365A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- amino
- aryl
- enamide
- prop
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 125000000217 alkyl group Chemical group 0.000 claims 139
- -1 perfluoro Chemical group 0.000 claims 122
- 125000003118 aryl group Chemical group 0.000 claims 66
- 125000000753 cycloalkyl group Chemical group 0.000 claims 64
- 125000001072 heteroaryl group Chemical group 0.000 claims 62
- 125000001424 substituent group Chemical group 0.000 claims 53
- 125000003342 alkenyl group Chemical group 0.000 claims 38
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 33
- 229910052739 hydrogen Inorganic materials 0.000 claims 29
- 239000001257 hydrogen Substances 0.000 claims 29
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 23
- 150000001875 compounds Chemical class 0.000 claims 23
- 229910052736 halogen Inorganic materials 0.000 claims 22
- 150000002367 halogens Chemical class 0.000 claims 20
- 229910052717 sulfur Inorganic materials 0.000 claims 20
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 15
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 15
- 125000000623 heterocyclic group Chemical group 0.000 claims 13
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 11
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 11
- 150000003839 salts Chemical class 0.000 claims 11
- 125000000304 alkynyl group Chemical group 0.000 claims 9
- 125000001041 indolyl group Chemical group 0.000 claims 9
- 229910052757 nitrogen Inorganic materials 0.000 claims 9
- 125000003386 piperidinyl group Chemical group 0.000 claims 9
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 claims 9
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 8
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 8
- 239000011593 sulfur Substances 0.000 claims 8
- 125000004434 sulfur atom Chemical group 0.000 claims 8
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 7
- 125000004076 pyridyl group Chemical group 0.000 claims 7
- 125000002047 benzodioxolyl group Chemical group O1OC(C2=C1C=CC=C2)* 0.000 claims 6
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims 6
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims 6
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 6
- 150000002431 hydrogen Chemical class 0.000 claims 6
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 claims 6
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 claims 6
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 claims 6
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims 6
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 5
- 125000003545 alkoxy group Chemical group 0.000 claims 5
- 125000004104 aryloxy group Chemical group 0.000 claims 5
- 125000002393 azetidinyl group Chemical group 0.000 claims 5
- 229910052799 carbon Inorganic materials 0.000 claims 5
- 125000004432 carbon atom Chemical group C* 0.000 claims 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 5
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 5
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 5
- 125000005843 halogen group Chemical group 0.000 claims 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 5
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 5
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 5
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 claims 5
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 5
- 125000005874 benzothiadiazolyl group Chemical group 0.000 claims 4
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims 4
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 125000005842 heteroatom Chemical group 0.000 claims 4
- 125000002757 morpholinyl group Chemical group 0.000 claims 4
- 229910052760 oxygen Inorganic materials 0.000 claims 4
- 125000005877 1,4-benzodioxanyl group Chemical group 0.000 claims 3
- RVMYORAOWOOBGC-UHFFFAOYSA-N 1-(4-amino-2-propan-2-ylquinolin-6-yl)-3-(4-phenoxyphenyl)urea Chemical compound C1=CC2=NC(C(C)C)=CC(N)=C2C=C1NC(=O)NC(C=C1)=CC=C1OC1=CC=CC=C1 RVMYORAOWOOBGC-UHFFFAOYSA-N 0.000 claims 3
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 claims 3
- 208000020925 Bipolar disease Diseases 0.000 claims 3
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 claims 3
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims 3
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 claims 3
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 3
- 125000004586 dihydrobenzopyranyl group Chemical group O1C(CCC2=C1C=CC=C2)* 0.000 claims 3
- 125000001070 dihydroindolyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 3
- 125000002541 furyl group Chemical group 0.000 claims 3
- 125000002632 imidazolidinyl group Chemical group 0.000 claims 3
- 125000002883 imidazolyl group Chemical group 0.000 claims 3
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 claims 3
- 125000005956 isoquinolyl group Chemical group 0.000 claims 3
- 125000001786 isothiazolyl group Chemical group 0.000 claims 3
- 125000000842 isoxazolyl group Chemical group 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 230000001404 mediated effect Effects 0.000 claims 3
- 125000001624 naphthyl group Chemical group 0.000 claims 3
- 125000001715 oxadiazolyl group Chemical group 0.000 claims 3
- 125000002971 oxazolyl group Chemical group 0.000 claims 3
- 125000004193 piperazinyl group Chemical group 0.000 claims 3
- 125000003373 pyrazinyl group Chemical group 0.000 claims 3
- 125000003226 pyrazolyl group Chemical group 0.000 claims 3
- 125000002098 pyridazinyl group Chemical group 0.000 claims 3
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 3
- 125000004550 quinolin-6-yl group Chemical group N1=CC=CC2=CC(=CC=C12)* 0.000 claims 3
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 3
- 125000005493 quinolyl group Chemical group 0.000 claims 3
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 claims 3
- 125000003831 tetrazolyl group Chemical group 0.000 claims 3
- 125000001113 thiadiazolyl group Chemical group 0.000 claims 3
- 125000000335 thiazolyl group Chemical group 0.000 claims 3
- 125000001544 thienyl group Chemical group 0.000 claims 3
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 claims 3
- 125000004306 triazinyl group Chemical group 0.000 claims 3
- 125000001425 triazolyl group Chemical group 0.000 claims 3
- FQYRLEXKXQRZDH-UHFFFAOYSA-N 4-aminoquinoline Chemical compound C1=CC=C2C(N)=CC=NC2=C1 FQYRLEXKXQRZDH-UHFFFAOYSA-N 0.000 claims 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 2
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 2
- 208000032841 Bulimia Diseases 0.000 claims 2
- 206010006550 Bulimia nervosa Diseases 0.000 claims 2
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 2
- 108010047068 Melanin-concentrating hormone receptor Proteins 0.000 claims 2
- 102000029828 Melanin-concentrating hormone receptor Human genes 0.000 claims 2
- 102100027375 Melanin-concentrating hormone receptor 1 Human genes 0.000 claims 2
- 108700036626 Melanin-concentrating hormone receptor 1 Proteins 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 2
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims 2
- 125000004622 benzoxazinyl group Chemical group O1NC(=CC2=C1C=CC=C2)* 0.000 claims 2
- 208000028683 bipolar I disease Diseases 0.000 claims 2
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 2
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 claims 2
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims 2
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 claims 2
- BZLBLJIDXKUVIY-UHFFFAOYSA-N n-(4-amino-2-propylquinolin-6-yl)-4-(4-chlorophenyl)benzamide Chemical compound C1=CC2=NC(CCC)=CC(N)=C2C=C1NC(=O)C(C=C1)=CC=C1C1=CC=C(Cl)C=C1 BZLBLJIDXKUVIY-UHFFFAOYSA-N 0.000 claims 2
- IODRBABXWALVGB-UHFFFAOYSA-N n-[4-(methylamino)-2-propylquinolin-6-yl]-4-[4-(trifluoromethyl)phenyl]benzamide Chemical compound C1=CC2=NC(CCC)=CC(NC)=C2C=C1NC(=O)C(C=C1)=CC=C1C1=CC=C(C(F)(F)F)C=C1 IODRBABXWALVGB-UHFFFAOYSA-N 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 2
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 2
- 125000000168 pyrrolyl group Chemical group 0.000 claims 2
- 201000000980 schizophrenia Diseases 0.000 claims 2
- MHCVCKDNQYMGEX-UHFFFAOYSA-N 1,1'-biphenyl;phenoxybenzene Chemical group C1=CC=CC=C1C1=CC=CC=C1.C=1C=CC=CC=1OC1=CC=CC=C1 MHCVCKDNQYMGEX-UHFFFAOYSA-N 0.000 claims 1
- RWANYXBMTWZYNJ-UHFFFAOYSA-N 1-(4-amino-2-propan-2-ylquinolin-6-yl)-3-(4-phenylcyclohexyl)urea Chemical compound C1=CC2=NC(C(C)C)=CC(N)=C2C=C1NC(=O)NC(CC1)CCC1C1=CC=CC=C1 RWANYXBMTWZYNJ-UHFFFAOYSA-N 0.000 claims 1
- QWFKLUVTPREHSE-UHFFFAOYSA-N 1-(4-amino-2-propan-2-ylquinolin-6-yl)-3-naphthalen-2-ylurea Chemical compound C1=CC=CC2=CC(NC(=O)NC3=CC4=C(N)C=C(N=C4C=C3)C(C)C)=CC=C21 QWFKLUVTPREHSE-UHFFFAOYSA-N 0.000 claims 1
- DJWDAKFSDBOQJK-UHFFFAOYSA-N 2,5-diazabicyclo[2.2.2]octane Chemical compound C1NC2CCC1NC2 DJWDAKFSDBOQJK-UHFFFAOYSA-N 0.000 claims 1
- HAMLPUFJIMQUED-UHFFFAOYSA-N 2-propyl-6-[5-[2-[4-(trifluoromethyl)phenyl]ethyl]-1,2,4-oxadiazol-3-yl]quinolin-4-amine Chemical compound C1=CC2=NC(CCC)=CC(N)=C2C=C1C(N=1)=NOC=1CCC1=CC=C(C(F)(F)F)C=C1 HAMLPUFJIMQUED-UHFFFAOYSA-N 0.000 claims 1
- 125000004608 5,6,7,8-tetrahydroquinolinyl group Chemical group N1=C(C=CC=2CCCCC12)* 0.000 claims 1
- 208000030507 AIDS Diseases 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 208000027559 Appetite disease Diseases 0.000 claims 1
- 206010003694 Atrophy Diseases 0.000 claims 1
- 206010006895 Cachexia Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- 206010012218 Delirium Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 206010013654 Drug abuse Diseases 0.000 claims 1
- 208000032928 Dyslipidaemia Diseases 0.000 claims 1
- 208000030814 Eating disease Diseases 0.000 claims 1
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 1
- 101150106280 Mchr1 gene Proteins 0.000 claims 1
- 208000019022 Mood disease Diseases 0.000 claims 1
- 206010061296 Motor dysfunction Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000004880 Polyuria Diseases 0.000 claims 1
- 208000000323 Tourette Syndrome Diseases 0.000 claims 1
- 208000016620 Tourette disease Diseases 0.000 claims 1
- 230000005856 abnormality Effects 0.000 claims 1
- 208000022531 anorexia Diseases 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 230000036528 appetite Effects 0.000 claims 1
- 235000019789 appetite Nutrition 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 230000037444 atrophy Effects 0.000 claims 1
- 208000025307 bipolar depression Diseases 0.000 claims 1
- 201000001883 cholelithiasis Diseases 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 206010061428 decreased appetite Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 235000014632 disordered eating Nutrition 0.000 claims 1
- 230000035619 diuresis Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 230000006870 function Effects 0.000 claims 1
- 208000001130 gallstones Diseases 0.000 claims 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 230000003907 kidney function Effects 0.000 claims 1
- 230000006386 memory function Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- JUVHCZDPIRYPPQ-UHFFFAOYSA-N n-(4-amino-2-propylquinolin-6-yl)-4-(4-chlorophenyl)cyclohexane-1-carboxamide Chemical compound C1=CC2=NC(CCC)=CC(N)=C2C=C1NC(=O)C(CC1)CCC1C1=CC=C(Cl)C=C1 JUVHCZDPIRYPPQ-UHFFFAOYSA-N 0.000 claims 1
- PDYKVAYDDJTAHL-UHFFFAOYSA-N n-(4-amino-2-propylquinolin-6-yl)-4-(4-ethylphenyl)benzamide Chemical compound C1=CC2=NC(CCC)=CC(N)=C2C=C1NC(=O)C(C=C1)=CC=C1C1=CC=C(CC)C=C1 PDYKVAYDDJTAHL-UHFFFAOYSA-N 0.000 claims 1
- RHMZTDUJISCDBB-UHFFFAOYSA-N n-(4-amino-2-propylquinolin-6-yl)-4-[4-(trifluoromethyl)phenyl]benzamide Chemical compound C1=CC2=NC(CCC)=CC(N)=C2C=C1NC(=O)C(C=C1)=CC=C1C1=CC=C(C(F)(F)F)C=C1 RHMZTDUJISCDBB-UHFFFAOYSA-N 0.000 claims 1
- CDWXGXBBYQEZMC-UHFFFAOYSA-N n-(4-amino-2-propylquinolin-6-yl)-4-phenylbenzamide Chemical compound C1=CC2=NC(CCC)=CC(N)=C2C=C1NC(=O)C(C=C1)=CC=C1C1=CC=CC=C1 CDWXGXBBYQEZMC-UHFFFAOYSA-N 0.000 claims 1
- VXKGIQLAOXGDMQ-UHFFFAOYSA-N n-[4-(azetidin-1-yl)-2-propylquinolin-6-yl]-4-(4-chlorophenyl)benzamide Chemical compound C=12C=C(NC(=O)C=3C=CC(=CC=3)C=3C=CC(Cl)=CC=3)C=CC2=NC(CCC)=CC=1N1CCC1 VXKGIQLAOXGDMQ-UHFFFAOYSA-N 0.000 claims 1
- NWRWXEOCZLOSKW-UHFFFAOYSA-N n-[4-amino-3-(hydroxymethyl)-2-propylquinolin-6-yl]-3-[4-(trifluoromethyl)phenyl]propanamide Chemical compound C1=C2C(N)=C(CO)C(CCC)=NC2=CC=C1NC(=O)CCC1=CC=C(C(F)(F)F)C=C1 NWRWXEOCZLOSKW-UHFFFAOYSA-N 0.000 claims 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 208000020016 psychiatric disease Diseases 0.000 claims 1
- 239000002464 receptor antagonist Substances 0.000 claims 1
- 229940044551 receptor antagonist Drugs 0.000 claims 1
- 230000001850 reproductive effect Effects 0.000 claims 1
- 230000036299 sexual function Effects 0.000 claims 1
- 230000035882 stress Effects 0.000 claims 1
- 208000011117 substance-related disease Diseases 0.000 claims 1
- 230000001629 suppression Effects 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- UXAWXZDXVOYLII-UHFFFAOYSA-N tert-butyl 2,5-diazabicyclo[2.2.1]heptane-2-carboxylate Chemical compound C1C2N(C(=O)OC(C)(C)C)CC1NC2 UXAWXZDXVOYLII-UHFFFAOYSA-N 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 0 *c(cc1)cc2c1nc(*)cc2N Chemical compound *c(cc1)cc2c1nc(*)cc2N 0.000 description 1
- UCLQANFPOHVOKR-UHFFFAOYSA-N C1C(C2)C3CC2C1C3 Chemical compound C1C(C2)C3CC2C1C3 UCLQANFPOHVOKR-UHFFFAOYSA-N 0.000 description 1
- KTZVZZJJVJQZHV-UHFFFAOYSA-N C=Cc(cc1)ccc1Cl Chemical compound C=Cc(cc1)ccc1Cl KTZVZZJJVJQZHV-UHFFFAOYSA-N 0.000 description 1
- KBRFVIHZIRAYRU-UHFFFAOYSA-N CC(Nc(cc1)cc2c1nc(CCCC1)c1c2N)=O Chemical compound CC(Nc(cc1)cc2c1nc(CCCC1)c1c2N)=O KBRFVIHZIRAYRU-UHFFFAOYSA-N 0.000 description 1
- XVDBUZZUOCJGQN-IZZDOVSWSA-N Nc1c(C(CCC2)O)c2nc(cc2)c1cc2NC(/C=C/c(cc1)ccc1Cl)=O Chemical compound Nc1c(C(CCC2)O)c2nc(cc2)c1cc2NC(/C=C/c(cc1)ccc1Cl)=O XVDBUZZUOCJGQN-IZZDOVSWSA-N 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33346401P | 2001-11-27 | 2001-11-27 | |
| PCT/US2002/037510 WO2003045920A1 (en) | 2001-11-27 | 2002-11-22 | 4-aminoquinoline compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005518365A JP2005518365A (ja) | 2005-06-23 |
| JP2005518365A5 true JP2005518365A5 (enExample) | 2006-01-05 |
Family
ID=23302904
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003547372A Withdrawn JP2005518365A (ja) | 2001-11-27 | 2002-11-22 | ４−アミノキノリン化合物 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20050009815A1 (enExample) |
| EP (1) | EP1451156A4 (enExample) |
| JP (1) | JP2005518365A (enExample) |
| AU (1) | AU2002352868A1 (enExample) |
| CA (1) | CA2468159A1 (enExample) |
| WO (1) | WO2003045920A1 (enExample) |
Families Citing this family (116)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2462200A1 (en) | 2001-08-10 | 2003-02-20 | Palatin Technologies, Inc. | Peptidomimetics of biologically active metallopeptides |
| BR0212787A (pt) * | 2001-09-24 | 2005-01-25 | Elan Pharm Inc | Composto ou sal farmaceuticamente aceitável do mesmo, métodos de tratamento ou prevenção de doenças e de preparação de um composto, uso de um composto ou sal, e, composição farmacêutica |
| CA2468015A1 (en) | 2001-11-27 | 2003-06-05 | Merck & Co., Inc. | 2-aminoquinoline compounds |
| CA2468544A1 (en) * | 2001-12-10 | 2003-06-19 | Amgen Inc. | Vanilloid receptor ligands |
| AR038420A1 (es) * | 2002-02-15 | 2005-01-12 | Glaxo Group Ltd | Compuesto de amida, procedimiento para la preparacion del mismo, su uso para la fabricacion de un medicamento y composicion farmaceutica que lo comprende |
| GB0205170D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
| GB0205166D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
| GB0205176D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
| GB0205165D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
| GB0205175D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
| GB0205162D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
| US6989392B2 (en) | 2002-06-18 | 2006-01-24 | Abbott Laboratories | 2-Aminoquinolines as melanin concentrating hormone receptor antagonists |
| ES2444550T3 (es) * | 2002-08-29 | 2014-02-25 | Temple University - Of The Commonwealth System Of Higher Education | Arilpropenamidas y heteroarilpropenamidas, derivados de las mismas y usos terapéuticos de las mismas |
| EP1558599A4 (en) * | 2002-10-30 | 2007-06-27 | Merck & Co Inc | HETEROARYLPIPERIDINE MODULATORS DERCHEMOKIN RECEPTORACTIVITY |
| US7351719B2 (en) | 2002-10-31 | 2008-04-01 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Amide compounds having MCH-antagonistic activity and medicaments comprising these compounds |
| CA2515717A1 (en) | 2003-02-10 | 2004-08-19 | Banyu Pharmaceutical Co., Ltd. | Melanin-concentrating hormone receptor antagonists containing piperidine derivatives as the active ingredient |
| TWI328009B (en) | 2003-05-21 | 2010-08-01 | Glaxo Group Ltd | Quinoline derivatives as phosphodiesterase inhibitors |
| EP1633718B1 (en) * | 2003-06-17 | 2012-06-06 | Millennium Pharmaceuticals, Inc. | COMPOSITIONS AND METHODS FOR INHIBITING TGF-s |
| GB0319150D0 (en) * | 2003-08-14 | 2003-09-17 | Glaxo Group Ltd | Novel compounds |
| AU2004265189B2 (en) * | 2003-08-15 | 2010-03-04 | Banyu Pharmaceutical Co., Ltd. | Imidazopyridine derivatives |
| EP1669348A4 (en) | 2003-09-30 | 2009-03-11 | Eisai R&D Man Co Ltd | NEW ANTIPILIC AGENT CONTAINING A HETEROCYCLIC COMPOUND |
| CA2540826A1 (en) | 2003-10-01 | 2005-04-14 | The Procter & Gamble Company | Melanin concentrating hormone antagonists |
| WO2005035521A1 (en) * | 2003-10-09 | 2005-04-21 | Argenta Discovery Ltd. | Substituted quinolines as mcr modulators |
| DE10360745A1 (de) * | 2003-12-23 | 2005-07-28 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Amid-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel |
| US7592373B2 (en) | 2003-12-23 | 2009-09-22 | Boehringer Ingelheim International Gmbh | Amide compounds with MCH antagonistic activity and medicaments comprising these compounds |
| US20090036448A1 (en) * | 2004-03-30 | 2009-02-05 | Taisho Pharmecutical Co., Ltd. | Pyrimidine derivatives and methods of treatment related to the use thereof |
| EP1729762A4 (en) * | 2004-03-31 | 2007-12-19 | Neurogen Corp | POLYTHERAPY FOR WEIGHT MANAGEMENT |
| US20080125403A1 (en) | 2004-04-02 | 2008-05-29 | Merck & Co., Inc. | Method of Treating Men with Metabolic and Anthropometric Disorders |
| WO2005108370A1 (ja) * | 2004-04-16 | 2005-11-17 | Ajinomoto Co., Inc. | ベンゼン化合物 |
| US7550499B2 (en) | 2004-05-12 | 2009-06-23 | Bristol-Myers Squibb Company | Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions |
| WO2006016548A1 (ja) * | 2004-08-09 | 2006-02-16 | Eisai R & D Management Co., Ltd. | ヘテロ環化合物を含有する新規な抗マラリア剤 |
| MX2007003332A (es) | 2004-09-20 | 2007-06-05 | Xenon Pharmaceuticals Inc | Derivados heterociclicos y su uso como inhibidores de estearoil-coa-desaturasa. |
| US20080167321A1 (en) * | 2004-09-20 | 2008-07-10 | Xenon Pharmaceuticals Inc. | Pyridine Derivatives For Inhibiting Human Stearoyl-Coa-Desaturase |
| EP2269610A3 (en) | 2004-09-20 | 2011-03-09 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors |
| AU2005305036B2 (en) * | 2004-11-01 | 2011-03-10 | Amylin Pharmaceuticals, Llc | Treatment of obesity and related disorders |
| ES2325773T5 (es) * | 2004-11-01 | 2014-02-24 | Amylin Pharmaceuticals, Llc. | Tratamiento de la obesidad y de los trastornos relacionados |
| US8394765B2 (en) | 2004-11-01 | 2013-03-12 | Amylin Pharmaceuticals Llc | Methods of treating obesity with two different anti-obesity agents |
| EP1807390A4 (en) * | 2004-11-04 | 2008-07-02 | Neurogen Corp | ARYL ALKYL UREA AS CB1 ANTAGONISTS |
| GB0428250D0 (en) * | 2004-12-23 | 2005-01-26 | Novartis Ag | Organic compounds |
| AU2006206611A1 (en) | 2005-01-19 | 2006-07-27 | Bristol-Myers Squibb Company | 2-phenoxy-N- (1, 3 , 4-thiadizol-2-yl) pyridin-3-amine derivatives and related compounds as P2Y1 receptor inhibitors for the treatment of thromboembolic disorders |
| JPWO2006104136A1 (ja) * | 2005-03-29 | 2008-09-11 | 萬有製薬株式会社 | 非アルコール性脂肪性肝疾患の治療剤、及び非アルコール性脂肪性肝疾患の治療又は予防のための薬剤の候補化合物のスクリーニング方法 |
| WO2006106711A1 (ja) | 2005-03-30 | 2006-10-12 | Eisai R & D Management Co., Ltd. | ピリジン誘導体を含有する抗真菌剤 |
| BRPI0611187A2 (pt) | 2005-06-03 | 2010-08-24 | Xenon Pharmaceuticals Inc | derivados aminotiazàis como inibidores da estearoil-coa desaturase humana |
| US7728008B2 (en) * | 2005-06-27 | 2010-06-01 | Bristol-Myers Squibb Company | N-linked heterocyclic antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions |
| DE602006020871D1 (de) | 2005-06-27 | 2011-05-05 | Bristol Myers Squibb Co | Lineare harnstoffmimetika-antagonisten des p2y1-rezeptors zur behandlung von thromboseleiden |
| US7714002B2 (en) * | 2005-06-27 | 2010-05-11 | Bristol-Myers Squibb Company | Carbocycle and heterocycle antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions |
| WO2007002635A2 (en) | 2005-06-27 | 2007-01-04 | Bristol-Myers Squibb Company | C-linked cyclic antagonists of p2y1 receptor useful in the treatment of thrombotic conditions |
| WO2007016292A2 (en) * | 2005-07-27 | 2007-02-08 | Vertex Pharmaceuticals Incorporated | Heterocyclic amides as biofilm modulators |
| AU2006279680B2 (en) | 2005-08-11 | 2012-12-06 | Amylin Pharmaceuticals, Llc | Hybrid polypeptides with selectable properties |
| BRPI0614649A2 (pt) | 2005-08-11 | 2011-04-12 | Amylin Pharmaceuticals Inc | polipeptìdeos hìbridos com propriedades selecionáveis |
| EP1917245A1 (de) | 2005-08-21 | 2008-05-07 | Abbott GmbH & Co. KG | Heterocyclische verbindungen und ihre verwendung als bindungspartner für 5-ht5-rezeptoren |
| TWI385169B (zh) | 2005-10-31 | 2013-02-11 | Eisai R&D Man Co Ltd | 經雜環取代之吡啶衍生物及含有彼之抗真菌劑 |
| JPWO2007063839A1 (ja) * | 2005-11-30 | 2009-05-07 | 塩野義製薬株式会社 | シクロヘキサン誘導体 |
| MX2008012738A (es) * | 2006-04-03 | 2009-02-06 | Astellas Pharma Inc | Heterocompuesto. |
| WO2008035726A1 (en) | 2006-09-21 | 2008-03-27 | Eisai R & D Management Co., Ltd. | Pyridine derivative substituted by heteroaryl ring, and antifungal agent comprising the same |
| US10954231B2 (en) | 2006-10-16 | 2021-03-23 | Bionomics Limited | Anxiolytic compounds |
| ES2399071T3 (es) | 2006-10-16 | 2013-03-25 | Bionomics Limited | Nuevos compuestos ansiolíticos |
| US7960569B2 (en) * | 2006-10-17 | 2011-06-14 | Bristol-Myers Squibb Company | Indole antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions |
| JP2010510202A (ja) | 2006-11-17 | 2010-04-02 | ファイザー株式会社 | 置換ビシクロカルボキシアミド化合物 |
| DE102007018149A1 (de) | 2007-04-16 | 2008-10-23 | Grünenthal GmbH | Neue Vanilloid-Rezeptor Liganden und ihre Verwendung zur Herstellung von Arzneimitteln |
| RU2498982C2 (ru) * | 2007-04-16 | 2013-11-20 | Грюненталь Гмбх | Новые лиганды ванилоидных рецепторов и их применение для изготовления лекарственных средств |
| CA2685194A1 (en) | 2007-04-27 | 2008-11-13 | Eisai R&D Management Co., Ltd. | Heterocycle-substituted pyridine derivatives salt or crystal thereof |
| TW200841879A (en) | 2007-04-27 | 2008-11-01 | Eisai R&D Man Co Ltd | Pyridine derivatives substituted by heterocyclic ring and phosphonoamino group, and anti-fungal agent containing same |
| WO2008142384A1 (en) * | 2007-05-17 | 2008-11-27 | Helperby Therapeutics Limited | Use of 4-(pyrrolidin-1-yl)quinoline compounds to kill clinically latent microorganisms |
| WO2009011336A1 (ja) * | 2007-07-18 | 2009-01-22 | Taisho Pharmaceutical Co., Ltd. | キノリン化合物 |
| JP5647519B2 (ja) | 2007-09-13 | 2014-12-24 | コンサート ファーマシューティカルズ インコーポレイテッド | 重水素化カテコールおよびベンゾ［ｄ］［１，３］ジオキソールおよびその誘導体の合成 |
| US8513287B2 (en) | 2007-12-27 | 2013-08-20 | Eisai R&D Management Co., Ltd. | Heterocyclic ring and phosphonoxymethyl group substituted pyridine derivatives and antifungal agent containing same |
| US8796216B2 (en) * | 2008-06-12 | 2014-08-05 | Syntaxin Limited | Suppression of neuroendocrine diseases |
| JP5580741B2 (ja) * | 2008-09-19 | 2014-08-27 | 武田薬品工業株式会社 | 含窒素複素環化合物およびその用途 |
| US8188119B2 (en) | 2008-10-24 | 2012-05-29 | Eisai R&D Management Co., Ltd | Pyridine derivatives substituted with heterocyclic ring and γ-glutamylamino group, and antifungal agents containing same |
| JP2012513464A (ja) | 2008-12-23 | 2012-06-14 | ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク | ホスホジエステラーゼ阻害剤及びその使用 |
| NZ603332A (en) * | 2010-04-02 | 2014-11-28 | Senomyx Inc | Sweet flavor modifier |
| JP2014510065A (ja) * | 2011-03-02 | 2014-04-24 | バイオノミックス リミテッド | 治療薬としての新規な小分子 |
| CN102229563A (zh) * | 2011-04-26 | 2011-11-02 | 常州大学 | 4-氨基喹啉衍生物及其制备方法和用途 |
| JP6055817B2 (ja) | 2011-05-12 | 2016-12-27 | バイオノミックス リミテッド | ナフチリジンの調製方法 |
| KR102001364B1 (ko) | 2011-05-13 | 2019-07-22 | 어레이 바이오파마 인크. | Trka 키나제 저해제로서의 피롤리디닐 유레아 및 피롤리디닐 티오유레아 화합물 |
| EP2742026B1 (en) * | 2011-08-12 | 2016-10-05 | Senomyx, Inc. | Sweet flavor modifier |
| RU2664541C2 (ru) | 2012-11-13 | 2018-08-20 | Эррэй Биофарма Инк. | Бициклические соединения мочевины, тиомочевины, гуанидина и цианогуанидина, пригодные для лечения боли |
| UA116455C2 (uk) | 2012-11-13 | 2018-03-26 | Еррей Біофарма Інк. | Сполуки n-піролідинілсечовини, n'-піразолілсечовини, тіосечовини, гуанідину та ціаногуанідину як інгібітори кінази trka |
| WO2014078325A1 (en) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | N-(monocyclic aryl),n'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
| WO2014078331A1 (en) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | N-(arylalkyl)-n'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
| WO2014078378A1 (en) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
| US9809578B2 (en) | 2012-11-13 | 2017-11-07 | Array Biopharma Inc. | Pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trkA kinase inhibitors |
| WO2014078328A1 (en) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | N-bicyclic aryl,n'-pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
| US9790178B2 (en) | 2012-11-13 | 2017-10-17 | Array Biopharma Inc. | Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors |
| US9981959B2 (en) | 2012-11-13 | 2018-05-29 | Array Biopharma Inc. | Thiazolyl and oxazolyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors |
| US9822118B2 (en) | 2012-11-13 | 2017-11-21 | Array Biopharma Inc. | Bicyclic heteroaryl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors |
| CA2900652C (en) | 2013-02-15 | 2021-05-04 | Kala Pharmaceuticals, Inc. | Therapeutic compounds and uses thereof |
| CN107915751A (zh) | 2013-02-20 | 2018-04-17 | 卡拉制药公司 | 治疗性化合物和其用途 |
| US9688688B2 (en) | 2013-02-20 | 2017-06-27 | Kala Pharmaceuticals, Inc. | Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof |
| US9890173B2 (en) | 2013-11-01 | 2018-02-13 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| WO2015066482A1 (en) | 2013-11-01 | 2015-05-07 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| CN109045032A (zh) | 2014-01-01 | 2018-12-21 | 麦迪威森技术有限责任公司 | 氨基吡啶类化合物和使用方法 |
| MY191956A (en) | 2014-05-15 | 2022-07-20 | Array Biopharma Inc | 1-((3s,4r)-4-(3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(2-methylpyrimidin-5-yl)-1-phenyl-1h-pyrazol-5-yl)urea as a trka kinase inhibitor |
| US11339128B2 (en) | 2014-11-07 | 2022-05-24 | Firmenich Incorporated | Substituted 4-amino-5-(cyclohexyloxy)quinoline-3-carboxylic acids as sweet flavor modifiers |
| WO2017019724A1 (en) | 2015-07-29 | 2017-02-02 | Merck Sharp & Dohme Corp. | Phenyl-cyanoquinolinone pde9 inhibitors |
| WO2017019723A1 (en) | 2015-07-29 | 2017-02-02 | Merck Sharp & Dohme Corp. | Aza-cyanoquinolinone pde9 inhibitors |
| US10370337B2 (en) | 2015-07-29 | 2019-08-06 | Merck, Sharp & Dohme Corp. | Oxy-cyanoquinolinone PDE9 inhibitors |
| US20190112317A1 (en) | 2015-10-05 | 2019-04-18 | The Trustees Of Columbia University In The City Of New York | Activators of autophagic flux and phospholipase d and clearance of protein aggregates including tau and treatment of proteinopathies |
| AU2017296392B2 (en) | 2016-07-14 | 2020-09-24 | Crinetics Pharmaceuticals, Inc. | Somatostatin modulators and uses thereof |
| AU2017324716B2 (en) | 2016-09-08 | 2020-08-13 | KALA BIO, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| AU2017324713B2 (en) | 2016-09-08 | 2020-08-13 | KALA BIO, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| MX2019002629A (es) | 2016-09-08 | 2019-10-07 | Kala Pharmaceuticals Inc | Formas cristalinas de compuestos terapéuticos y usos de los mismos. |
| TW201815762A (zh) | 2016-09-21 | 2018-05-01 | 德商歌林達有限公司 | 經尿素及苯基取代之６員環狀胺或內醯胺 |
| EP3658560A4 (en) | 2017-07-25 | 2021-01-06 | Crinetics Pharmaceuticals, Inc. | SOMATOSTAT IN MODULATORS AND USES THEREOF |
| GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
| US12459965B2 (en) | 2017-10-09 | 2025-11-04 | Compass Pathfinder Limited | Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use |
| EP3717472B1 (en) * | 2017-11-27 | 2022-07-27 | F. Hoffmann-La Roche AG | Pyrimidine derivatives |
| MA51625B1 (fr) * | 2018-01-17 | 2022-07-29 | Crinetics Pharmaceuticals Inc | Procédé de production de modulateurs de somatostatine |
| JP2022529781A (ja) | 2019-04-17 | 2022-06-24 | コンパス パスファインダー リミテッド | サイロシビンによるうつ病及び他の様々な障害の治療 |
| US12617767B2 (en) | 2019-07-17 | 2026-05-05 | Crinetics Pharmaceuticals, Inc. | Crystalline forms of somatostatin modulators |
| CN114269720B (zh) * | 2019-07-25 | 2025-03-28 | 库拉德夫制药私人有限公司 | 乙酰辅酶a合成酶短链2(acss2)的小分子抑制剂 |
| WO2022055880A1 (en) | 2020-09-09 | 2022-03-17 | Crinetics Pharmaceuticals, Inc. | Formulations of a somatostatin modulator |
| CZ309225B6 (cs) * | 2021-01-26 | 2022-06-01 | Fakultní nemocnice Hradec Králové | 7-Fenoxytakrin a jeho použití |
| CZ309262B6 (cs) * | 2021-01-26 | 2022-06-29 | Fakultní nemocnice Hradec Králové | Duálně účinné deriváty takrinu a jejich použit |
| CN117843616B (zh) * | 2023-12-26 | 2025-05-27 | 中国药科大学 | 3-氰基取代喹啉类化合物及其药物组合物和应用 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3856796A (en) * | 1972-04-19 | 1974-12-24 | Sandoz Ag | Hydroxyalkyl-substituted-amino-quinolines and nitrates thereof |
| US3957791A (en) * | 1972-09-25 | 1976-05-18 | Sandoz, Inc. | Hydroxyalkyl-piperazino-quinoline nitrates |
| US4013665A (en) * | 1973-10-01 | 1977-03-22 | Bristol-Myers Company | Antiviral, substituted 1,3-dimethyl-1h-pyrazolo(3,4b)quinolines |
| US4035367A (en) * | 1974-09-09 | 1977-07-12 | Sandoz, Inc. | Hydroxyalkyl-substituted-amino-quinolines |
| US4701459A (en) * | 1986-07-08 | 1987-10-20 | Bristol-Myers Company | 7-amino-1,3-dihydro-2H-imidazo[4,5-b]quinolin 2-ones and method for inhibiting phosphodiesterase and blood platelet aggregation |
| AU5812498A (en) * | 1996-12-20 | 1998-07-17 | Merck & Co., Inc. | Substituted aminoquinolines as modulators of chemokine receptor activity |
| US5942520A (en) * | 1998-01-27 | 1999-08-24 | Cell Pathways, Inc. | Method for inhibiting neoplastic cells by exposure to substituted N-cycloalkylmethyl-1-H-pyrazolo (3,4-B) quinolone-4 amines |
| EP0982300A3 (en) * | 1998-07-29 | 2000-03-08 | Societe Civile Bioprojet | Non-imidazole alkylamines as histamine H3 - receptor ligands and their therapeutic applications |
| US6221613B1 (en) * | 1998-12-31 | 2001-04-24 | Synaptic Pharmaceutical Corporation | DNA encoding a human melanin concentrating hormone receptor (MCH1) and uses thereof |
| US6720324B2 (en) * | 2000-07-05 | 2004-04-13 | Synaptic Pharmaceutical Corporation | Selective melanin concentrating hormone-1 (MCH1) receptor antagonists and uses thereof |
| US6569861B2 (en) * | 2000-07-06 | 2003-05-27 | Neurogen Corporation | Melanin concentrating hormone receptor ligands |
| US6900329B2 (en) * | 2001-03-21 | 2005-05-31 | Schering Corporation | MCH antagonists and their use in the treatment of obesity |
| WO2002089729A2 (en) * | 2001-05-04 | 2002-11-14 | Tularik Inc. | Fused heterocyclic compounds |
| US6727264B1 (en) * | 2001-07-05 | 2004-04-27 | Synaptic Pharmaceutical Corporation | Substituted anilinic piperidines as MCH selective antagonists |
| EP1443922A1 (en) * | 2001-10-25 | 2004-08-11 | Schering Corporation | Mch antagonists for the treatment of obesity |
| US6818772B2 (en) * | 2002-02-22 | 2004-11-16 | Abbott Laboratories | Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor |
| AU2003243497A1 (en) * | 2002-06-12 | 2003-12-31 | Millennium Pharmaceuticals, Inc. | Antagonists of melanin concentrating hormone receptor |
| AU2003259131A1 (en) * | 2002-07-09 | 2004-01-23 | Bristol-Myers Squibb Company | Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method |
-
2002
- 2002-11-22 EP EP02789827A patent/EP1451156A4/en not_active Withdrawn
- 2002-11-22 CA CA002468159A patent/CA2468159A1/en not_active Abandoned
- 2002-11-22 WO PCT/US2002/037510 patent/WO2003045920A1/en not_active Ceased
- 2002-11-22 AU AU2002352868A patent/AU2002352868A1/en not_active Abandoned
- 2002-11-22 US US10/496,614 patent/US20050009815A1/en not_active Abandoned
- 2002-11-22 JP JP2003547372A patent/JP2005518365A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005519876A5 (enExample) | ||
| CN109195602B (zh) | 用作免疫调节剂的对称或半对称化合物 | |
| JP5487214B2 (ja) | キナーゼ阻害剤として有用なカルバゾールカルボキシアミド化合物 | |
| CA2509565A1 (en) | Mitogen activated protein kinase-activated protein kinase-2 inhibiting compounds | |
| AU2009327127A1 (en) | Cyclic pyrimidin-4-carboxamides as CCR2 receptor antagonists for treatment of inflammation, asthma and COPD | |
| JP6077468B2 (ja) | 不斉尿素及びその医学的用途 | |
| RU2007119784A (ru) | Бициклические производные пиримидина, ингибирующие вич | |
| CN110546140A (zh) | 选择性hdac6抑制剂 | |
| JP2009530345A5 (enExample) | ||
| RU2008135364A (ru) | Соединения трехзамещенного амина и их применение в качестве ингибиторов белка переноса холестеринового эфира (сетр) | |
| BR112012015873B1 (pt) | Antagonistas de receptores ccr2 | |
| RU2009105398A (ru) | Замещенные гетероарильные производные | |
| CA2392584A1 (en) | Substituted pyridazines having cytokine inhibitory activity | |
| AU2014234906A1 (en) | Cycloalkyl nitrile pyrazolo pyridones as Janus kinase inhibitors | |
| US7473695B2 (en) | 4-imidazolin-2-one compounds | |
| JP2007532611A (ja) | １−アミノ−フタラジン誘導体、これらの調製及び治療的使用 | |
| CA2598536A1 (en) | Oxyindole derivatives as 5ht4 receptor agonists | |
| AU2003290744A1 (en) | Indolyl pyrazinone derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | |
| US9745282B2 (en) | Indoline compounds as aldosterone synthase inhibitors | |
| CA2461100C (en) | 4-imidazolin-2-one compounds | |
| JP2007534719A (ja) | 置換５，６，７，８−テトラヒドロ−ピリド［４，３−ｄ］ピリミジン−２−イル化合物および５，６，７，８−テトラヒドロ−キナゾリン−２−イル化合物 | |
| CN116669737A (zh) | 毒蕈碱型乙酰胆碱受体m4的拮抗剂 | |
| JP2007537255A5 (enExample) | ||
| CA2842976A1 (en) | Substituted bicyclic aromatic carboxamide and urea derivatives as vanilloid receptor ligands | |
| TW200401777A (en) | Spirosubstituted piperidines as selective melanin concentrating hormone receptor antagonists for the treatment of obesity |